financetom
Business
financetom
/
Business
/
Velo3D Appoints James Suva as CFO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Velo3D Appoints James Suva as CFO
Mar 25, 2026 6:47 AM

09:21 AM EDT, 03/25/2026 (MT Newswires) -- Velo3D ( VELO ) said Wednesday it has appointed James Suva as chief financial officer, starting April 6.

Suva succeeds acting CFO Bernard Chung, who will continue to serve as controller, the company said.

Suva most recently worked as senior vice president and treasurer at Cricut ( CRCT ) , Velo3D ( VELO ) said.

Shares of the company were down 8% in Wednesday premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Form 8.3 - Spectris plc
Form 8.3 - Spectris plc
Oct 17, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Balyasny Asset Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...
Neurocrine Biosciences Says Late-Stage Movement Disorder Study Shows Ingrezza's Therapeutic Efficacy at Lowest Available Dose
Neurocrine Biosciences Says Late-Stage Movement Disorder Study Shows Ingrezza's Therapeutic Efficacy at Lowest Available Dose
Oct 17, 2025
09:29 AM EDT, 10/17/2025 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said Friday that a new post-hoc analysis of a late-stage study showed clinically meaningful improvements in tardive dyskinesia symptoms in patients treated with Ingrezza at the lowest available dose of 40 mg. The company said 90% of participants who received continuous treatment for 48 weeks improved by at...
AbbVie Closes Bretisilocin Acquisition
AbbVie Closes Bretisilocin Acquisition
Oct 17, 2025
09:28 AM EDT, 10/17/2025 (MT Newswires) -- AbbVie ( ABBV ) said Friday it has closed the acquisition of Gilgamesh Pharmaceuticals' lead investigational candidate bretisilocin. Bretisilocin is a psychedelic compound in phase 2 clinical development for the treatment of patients with moderate to severe major depressive disorder, AbbVie ( ABBV ) said. ...
Visionary Completes Controlling Stake in Sikang Health Industry Joint Venture Platform, Deepening Global Layout of TCM Health Preservation
Visionary Completes Controlling Stake in Sikang Health Industry Joint Venture Platform, Deepening Global Layout of TCM Health Preservation
Oct 17, 2025
TORONTO, Oct. 17, 2025 /PRNewswire/ -- Visionary Holdings Inc. ( GV ) , a Nasdaq-listed enterprise, announced today that it has completed the equity adjustment of Sikang (Guangzhou) Health Industry Investment Co., Ltd. (hereinafter referred to as the Joint Venture Company), a joint venture established with Guangzhou Sikang Investment Holding Co., Ltd. (hereinafter referred to as Guangzhou Sikang), and officially...
Copyright 2023-2026 - www.financetom.com All Rights Reserved